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The global scientific community is going to blast off 
to the Moon again with the clear aim to cure cancer 
47  years after man first stepped onto the lunar surface. 
President Obama signed a Presidential Memorandum at 
the beginning of 2016—White House Cancer Moonshot 
Task Force—and called upon the world to “cure cancer 
once and for all”.
It is a new milestone and effort to re-unite scientific 
resources and experts, optimize therapeutic strate-
gies and improve outcomes of patients with cancer. The 
Cancer Moonshot initiative delivers a number of oppor-
tunities and challenges, e.g., how can we integrate the 
Moonshot program with other anti-cancer strategies like 
clinical and translational medicine or precision medicine; 
how do we define focus points; how do we monitor pro-
gress along the “Moonshot” voyage?
The cancer research community is ready for the Moon-
shot 2020 program, although there are still a large num-
ber of thresholds, hurdles and obstacles to be determined 
and resolved along the way. A number of advanced bio-
technologies in genomics, proteomics, metabolomics, 
systems biology, clinical bioinformatics and drug discov-
ery have been translated into clinical practices and appli-
cations. Great potential lies in single-cell biology as well 
as in the study of the 3D architecture and organization 
of the genome, also known as gene repositioning. New 
therapies for gene editing, cell targeting, and immune 
approaches give the Cancer Moonshot 2020 program 
the ammunition required to reach its goals. For example, 
preclinical studies have shown the potential for multi-
plexed genome editing in in vitro and in vivo systems by 
CRISPR/Cas-mediated gene editing. Wang et al. simulta-
neously interrupted five distinct alleles in mouse embry-
onic stem cells, with an efficiency of 80 % to achieve the 
one-step generation of animals carrying mutations in 
multiple genes [1]. Transcription activator-like effector 
nucleases (TALENs) and clustered regularly interspaced 
short palindromic repeats (CRISPR)–Cas9 nucleases 
have been suggested as the most commonly employed 
approaches to edit the human genome.
Another exciting development is the application of 
antibodies in the inhibition of endogenous immune 
responses to cancer, known as checkpoint blockade ther-
apy. Clinical trials have proved the safety and efficacy 
of antibodies that block the T cell inhibitory molecules 
CTLA-4 and PD-1 in treating subsets of patients with 
metastatic melanoma and renal cell carcinoma [2]. There 
is however quite some discussion about the types of can-
cer that would be most suitable for intervention using 
immunotherapy and there is great interest in specific 
biomarkers to monitor the various responses to these 
therapies.
We should also consider the potential for overlap and 
cooperation between the Cancer Moonshot 2020 pro-
gram and clinical and translational medicine, and preci-
sion medicine. One part of the Cancer Moonshot 2020 
program is to use progress in clinical and translational 
medicine, to re-unite, re-collect, re-organize, and re-opti-
mize resources to fight diseases [3, 4].
Clinical and translational medicine was initiated 
10 years ago to foster the communication between basic 
and clinical scientists, to translate advanced biotechnolo-
gies into clinical practice, and to improve the quality of 
life for patients. Precision medicine was announced in 
2015 as a new emerging area and therapeutic strategy to 
improve the treatment and prognosis of patients by inte-
grating clinical phenotypes with bioinformatics, com-
putational science, mathematics, gene sequencing and 
systems biology.
Precision medicine was proposed, containing five criti-
cal elements: clinical bioinformatics, precision meth-
odologies, disease-specific biomarkers, drug discovery 
and development, and precision regulations to guard 
the application of precision medicine [5]. A gene-based 
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therapeutic strategy was initially suggested for inherited 
diseases and cancers on the basis of gene mutation and 
heterogeneity, and it was then later extended to include 
metabolic and cardiovascular diseases. Precision medi-
cine could be one of the therapeutic strategies in the pro-
gram of Cancer Moonshot 2020 program, or the program 
could be one of the therapeutic areas of focus in preci-
sion medicine.
The Cancer Moonshot initiative will promote the col-
laboration of all potential resources and it will improve 
the ability to:
  • detect and prevent cancer at an early stage,
  • develop cancer vaccination, immunotherapy, and 
combination therapy,
  • perform genomic analysis of tumor and surrounding 
cells,
  • allow enhanced data sharing,
  • establish more oncology center of excellence, and
  • develop more therapies for pediatric cancer [6].
The “White House Cancer Moonshot Task Force” was 
defined as a national program, government-led com-
mission, Federal investments-dominated research, and 
cancer-focused therapy [7]. However, the fight against 
cancer is a global issue, which will greatly benefit from 
the involvement and contribution of the entire scien-
tific community, focusing on a clear global strategy. To 
be able to effectively tackle the issues ahead, we need to 
develop a better understanding of cellular structures, 
organelles, functioning properties, metabolic circles, 
signaling pathways or interactions, and of the tumor 
microenvironment.
We should identify molecular targets during the dis-
covery and development of target-based drugs and have 
biological function- and disease-specific biomarkers 
to monitor drug efficacy, efficiency and toxicology. We 
should have a better understanding of alterations of spa-
tial genome organization and its effect on transcription 
as well as of higher-order chromosome folding and spe-
cific chromatin interactions in the topological mecha-
nism of human cancer [8].
The Cancer Moonshot is a new ‘giant leap’ for clinical 
and translational medicine, a new opportunity to opti-
mize scientific achievements and advances to cure can-
cer, with a special focus on cancer prevention and early 
detection and treatment.
The success of the Cancer Moonshot 2020 program 
will also be dependent upon the sharing of databases, 
which include clinical information, patient phenotypes, 
imaging, biochemical measurements, therapies, gene 
sequencing and systems biology.
We therefore believe that clinical and translational 
medicine will play an important role in the achievement 
of the goals set out in the Cancer Moonshot 2020 pro-
gram. Cancer Moonshot “Apollo 11” has been launched 
and the anti-cancer spacecraft have started their voyage; 
the countdown to cure cancer has begun.
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